🔗 Share this article

Given that the US continues making historic revisions to its vaccination schedules, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on Covid vaccines in the global health crisis and has concentrated on possible fatalities following Covid vaccination in her short tenure at the FDA.

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities planned to unveil sweeping revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of alignment with many the global community with insufficient data for public health gain. This reveal has been postponed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to run the office this year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain pediatric shot schedules in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – usually the domain of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Questions Over Background

Høeg has no obvious experience in medication creation, approval processes or management, which has been typical for past directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Jonathan Howard. “She’s never run a scientific study. She has no expertise in managing a large organization. She has no expertise in industry regulation.”

Former commissioners of CBER would “understand legal statutes and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the kind of background that former directors who led the center have had.”

The drug center has an vast range of responsibilities at the FDA, the former commissioner stated.

“The public just zeroes in on the new drug program, but the off-patent medication office clears a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and all of those need to be looked after,” Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the position, which oversees more than 5,000 employees. “It is a enormous administrative position, if you execute it properly,” Woodcock added.

Agency Reaction and Contentious Initiatives

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment indicates greater collaboration among FDA leaders on immunizations, a spokesperson said that the “inquiries are based on flawed assumptions”.

“Her experience aligns with the functions of her role,” the representative said, noting the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s recently launched priority voucher program, a contentious one-day medication authorization process that apparently worried her predecessors. “How are these therapies being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, except for immunizations.”

Documented Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if concerning, track record, some experts observe. She authored a analysis using unverified public submissions to determine the frequency of myocarditis after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership encompassed altering rules for recently developed shots and ending “unnecessary” immunizations, she stated after the election on a podcast. At the agency, Høeg has according to sources suggested excluding teenage boys from getting COVID-19 vaccines.

“She is an thorough ideologue who begins with her preconceived notions and works backwards to retrofit the science in a very deceptive, dishonest way,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|